Veracyte licenses NanoString diagnostic platform in $50M deal

By staff writers

December 4, 2019 -- Veracyte is set to pay $50 million -- $40 million in cash and the rest in common stock -- for an exclusive global license to the NanoString nCounter diagnostics platform. The company said the deal will power the international expansion of its genomics products, especially its investigational nasal swab test for lung cancer.

Per the deal, NanoString is due another $10 million as Veracyte's tests are launched on the platform commercially. NanoString's platform enables the simultaneous analysis of RNA, DNA, or protein targets for up to 800 genes.

Veracyte's first priority as part of the agreement is to introduce its Envisia classifier for detecting idiopathic pulmonary fibrosis for use in a kit-based test that runs on the nCounter platform. Veracyte is targeting an international launch date for Envisia of 2021, which it will follow with an introduction of the new nasal swab genomic test in 2022.

The deal also includes the acquisition of other products: NanoString Prosigna, which assesses prognosis in breast cancer patients, and the investigational LymphMark test, which analyzes lymphoma subtypes.

AMP highlights: Products aim to beat the clock in cancer detection
Cancer was a key focus at the recent Association for Molecular Pathology (AMP) annual meeting in Baltimore -- particularly faster detection and treatment...
Veracyte nasal swab test holds its own in lung cancer detection
Veracyte said the accuracy of its investigational nasal swab genomic classifying test rivals the clinical standard for lung nodule assessment and has...
Veracyte validates Afirma XA in thyroid cancer
Veracyte published data in Frontiers in Endocrinology on September 11 supporting the utility of its Afirma Expression Atlas (XA) test for identifying...
Popular rule-out test for thyroid cancer draws scrutiny
Researchers are questioning whether a commonly used gene expression classifier test for evaluating indeterminate thyroid nodules lives up to expectations,...

Copyright © 2019

Last Updated eh 12/4/2019 4:36:41 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.